Douglas Pharmaceuticals, a New Zealand-owned generic drug manufacturer serving local and export markets, is to stay in family ownership after testing the market following numerous approaches from would-be buyers.
Founder and managing director Sir Graeme Douglas has backed keeping the Henderson-based company in family ownership after the company held a formal tender process through an information memorandum to prospective buyers.
A number of offers had been received over the years, but the firm says it has decided that staying with private owners was best for its future. It plans to bolster its export activities by hiring new executives to focus on emerging markets in Asia and Latin America.
"Along with my board, I remain committed and passionate about the future of our New Zealand-manufactured pharmaceuticals enjoying ever-increasing success in the world markets," Sir Graeme says.
Douglas Pharmaceuticals was set up in 1967 and sells 15 products into 35 countries, with export turnover of some $85 million.
It ranks number 11 in the TIN100, an annually produced survey that identifies New Zealand's top 100 high-value research and technology firms.
It turned over $127.8 million in the 2012 financial year and has secured US Federal Drug Administration accreditation and global distribution agreements for three key dermatology treatments.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Rich Lister John Spencer of Caxton paper fame dies
- Intueri suspends dividends, warns of regulatory hit
- MARKET CLOSE: NZ shares fall on underwhelming SkyCity outlook; Xero, MRP decline
- Auckland Council, James Hardie appeal ruling on leaky building claim made beyond 10-year limit
- NZ POLITICS DAILY: The new critics of Waitangi
Most listened to
- Tech commentator Paul Brislen breaks down the latest telco sector report
- NBR reporter Tim Hunter discusses Intueri's problems
- NZ ambassador to Turkey Jonathan Curr talks about improving Turkish - NZ relations
- Hamish McNicol discusses Masala Restaurants and Kim Dotcom in this week's Court Report
- Conflict controversies, increased sports rights competition and MIA IPOs: Chelsea Armitage and Nick Grant on NZ media